ResMed Inc. (RMD) Stock Competitors & Peer Comparison
See (RMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RMD | $193.14 | -1.48% | 28B | 18.63 | $10.37 | +1.24% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $90.50 | -0.63% | 157.5B | 25.33 | $3.57 | +2.69% |
| ISRG | $418.61 | -0.82% | 148.2B | 50.86 | $8.23 | N/A |
| SYK | $301.53 | -1.35% | 115.6B | 34.86 | $8.65 | +1.14% |
| MDT | $80.69 | -1.20% | 103.6B | 21.63 | $3.73 | +3.52% |
| BSX | $48.70 | +0.31% | 72.4B | 20.38 | $2.39 | N/A |
| BRKRP | $419.49 | -0.41% | 63.7B | N/A | N/A | +0.36% |
| EW | $85.85 | -0.13% | 49.4B | 46.41 | $1.85 | N/A |
| DXCM | $76.62 | +5.16% | 29.6B | 32.88 | $2.33 | N/A |
Stock Comparison
RMD vs BSX-PA Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RMD is priced at $193.14, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RMD's ROE is +0.24%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSX-PA's competition here
RMD vs ABT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ABT has a market cap of 157.5B. Regarding current trading prices, RMD is priced at $193.14, while ABT trades at $90.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ABT's P/E ratio is 25.33. In terms of profitability, RMD's ROE is +0.24%, compared to ABT's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ABT's competition here
RMD vs ISRG Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ISRG has a market cap of 148.2B. Regarding current trading prices, RMD is priced at $193.14, while ISRG trades at $418.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ISRG's P/E ratio is 50.86. In terms of profitability, RMD's ROE is +0.24%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ISRG's competition here
RMD vs SYK Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SYK has a market cap of 115.6B. Regarding current trading prices, RMD is priced at $193.14, while SYK trades at $301.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SYK's P/E ratio is 34.86. In terms of profitability, RMD's ROE is +0.24%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RMD is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SYK's competition here
RMD vs MDT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, MDT has a market cap of 103.6B. Regarding current trading prices, RMD is priced at $193.14, while MDT trades at $80.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas MDT's P/E ratio is 21.63. In terms of profitability, RMD's ROE is +0.24%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MDT's competition here
RMD vs BSX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BSX has a market cap of 72.4B. Regarding current trading prices, RMD is priced at $193.14, while BSX trades at $48.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BSX's P/E ratio is 20.38. In terms of profitability, RMD's ROE is +0.24%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSX's competition here
RMD vs BRKRP Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BRKRP has a market cap of 63.7B. Regarding current trading prices, RMD is priced at $193.14, while BRKRP trades at $419.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BRKRP's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BRKRP's competition here
RMD vs EW Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, RMD is priced at $193.14, while EW trades at $85.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas EW's P/E ratio is 46.41. In terms of profitability, RMD's ROE is +0.24%, compared to EW's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EW's competition here
RMD vs DXCM Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, RMD is priced at $193.14, while DXCM trades at $76.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas DXCM's P/E ratio is 32.88. In terms of profitability, RMD's ROE is +0.24%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, RMD is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check DXCM's competition here
RMD vs PHG Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PHG has a market cap of 25.1B. Regarding current trading prices, RMD is priced at $193.14, while PHG trades at $25.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PHG's P/E ratio is 22.25. In terms of profitability, RMD's ROE is +0.24%, compared to PHG's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check PHG's competition here
RMD vs STE Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, STE has a market cap of 20.5B. Regarding current trading prices, RMD is priced at $193.14, while STE trades at $210.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas STE's P/E ratio is 26.53. In terms of profitability, RMD's ROE is +0.24%, compared to STE's ROE of +0.11%. Regarding short-term risk, RMD is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check STE's competition here
RMD vs ABMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RMD is priced at $193.14, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RMD's ROE is +0.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ABMD's competition here
RMD vs ZBH Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ZBH has a market cap of 16.9B. Regarding current trading prices, RMD is priced at $193.14, while ZBH trades at $87.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ZBH's P/E ratio is 22.62. In terms of profitability, RMD's ROE is +0.24%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RMD is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ZBH's competition here
RMD vs SNN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, RMD is priced at $193.14, while SNN trades at $30.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SNN's P/E ratio is 21.22. In terms of profitability, RMD's ROE is +0.24%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SNN's competition here
RMD vs PEN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, RMD is priced at $193.14, while PEN trades at $320.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PEN's P/E ratio is 73.91. In terms of profitability, RMD's ROE is +0.24%, compared to PEN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check PEN's competition here
RMD vs SWAV Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RMD is priced at $193.14, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RMD's ROE is +0.24%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SWAV's competition here
RMD vs ALGN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ALGN has a market cap of 12.3B. Regarding current trading prices, RMD is priced at $193.14, while ALGN trades at $172.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ALGN's P/E ratio is 28.92. In terms of profitability, RMD's ROE is +0.24%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ALGN's competition here
RMD vs GMED Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, RMD is priced at $193.14, while GMED trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas GMED's P/E ratio is 18.30. In terms of profitability, RMD's ROE is +0.24%, compared to GMED's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GMED's competition here
RMD vs PODD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PODD has a market cap of 10.5B. Regarding current trading prices, RMD is priced at $193.14, while PODD trades at $151.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PODD's P/E ratio is 35.40. In terms of profitability, RMD's ROE is +0.24%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RMD is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PODD's competition here
RMD vs MASI Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RMD is priced at $193.14, while MASI trades at $179.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas MASI's P/E ratio is 44.54. In terms of profitability, RMD's ROE is +0.24%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MASI's competition here
RMD vs BRKR Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, RMD is priced at $193.14, while BRKR trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BRKR's P/E ratio is -234.42. In terms of profitability, RMD's ROE is +0.24%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RMD is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BRKR's competition here
RMD vs BIO-B Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BIO-B has a market cap of 8.3B. Regarding current trading prices, RMD is priced at $193.14, while BIO-B trades at $307.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BIO-B's P/E ratio is 51.10. In terms of profitability, RMD's ROE is +0.24%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RMD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BIO-B's competition here
RMD vs BIO Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BIO has a market cap of 7.9B. Regarding current trading prices, RMD is priced at $193.14, while BIO trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BIO's P/E ratio is 48.58. In terms of profitability, RMD's ROE is +0.24%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RMD is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BIO's competition here
RMD vs GKOS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, GKOS has a market cap of 7.2B. Regarding current trading prices, RMD is priced at $193.14, while GKOS trades at $121.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas GKOS's P/E ratio is -37.00. In terms of profitability, RMD's ROE is +0.24%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, RMD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GKOS's competition here
RMD vs NARI Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RMD is priced at $193.14, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas NARI's P/E ratio is -59.24. In terms of profitability, RMD's ROE is +0.24%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check NARI's competition here
RMD vs LIVN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, RMD is priced at $193.14, while LIVN trades at $74.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas LIVN's P/E ratio is 38.16. In terms of profitability, RMD's ROE is +0.24%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RMD is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LIVN's competition here
RMD vs AXNX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RMD is priced at $193.14, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RMD's ROE is +0.24%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AXNX's competition here
RMD vs IRTC Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, RMD is priced at $193.14, while IRTC trades at $107.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas IRTC's P/E ratio is -126.15. In terms of profitability, RMD's ROE is +0.24%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IRTC's competition here
RMD vs ITGR Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, RMD is priced at $193.14, while ITGR trades at $91.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ITGR's P/E ratio is 22.79. In terms of profitability, RMD's ROE is +0.24%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RMD is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ITGR's competition here
RMD vs TMDX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, RMD is priced at $193.14, while TMDX trades at $71.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas TMDX's P/E ratio is 16.28. In terms of profitability, RMD's ROE is +0.24%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RMD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TMDX's competition here
RMD vs AXGN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, RMD is priced at $193.14, while AXGN trades at $41.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas AXGN's P/E ratio is -64.78. In terms of profitability, RMD's ROE is +0.24%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AXGN's competition here
RMD vs ESTA Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, RMD is priced at $193.14, while ESTA trades at $74.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ESTA's P/E ratio is -50.91. In terms of profitability, RMD's ROE is +0.24%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RMD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ESTA's competition here
RMD vs NUVA Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $193.14, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RMD's ROE is +0.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NUVA's competition here
RMD vs UFPT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, RMD is priced at $193.14, while UFPT trades at $226.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas UFPT's P/E ratio is 25.82. In terms of profitability, RMD's ROE is +0.24%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check UFPT's competition here
RMD vs PRCT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, RMD is priced at $193.14, while PRCT trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PRCT's P/E ratio is -15.49. In terms of profitability, RMD's ROE is +0.24%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RMD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PRCT's competition here
RMD vs ENOV Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, RMD is priced at $193.14, while ENOV trades at $23.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ENOV's P/E ratio is -1.19. In terms of profitability, RMD's ROE is +0.24%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, RMD is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ENOV's competition here
RMD vs IART Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $193.14, while IART trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas IART's P/E ratio is -2.62. In terms of profitability, RMD's ROE is +0.24%, compared to IART's ROE of -0.48%. Regarding short-term risk, RMD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IART's competition here
RMD vs AHCO Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $193.14, while AHCO trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas AHCO's P/E ratio is -16.36. In terms of profitability, RMD's ROE is +0.24%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RMD is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AHCO's competition here
RMD vs HSKA Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $193.14, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RMD's ROE is +0.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check HSKA's competition here
RMD vs TNDM Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $193.14, while TNDM trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas TNDM's P/E ratio is -13.48. In terms of profitability, RMD's ROE is +0.24%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, RMD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TNDM's competition here
RMD vs BFLY Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $193.14, while BFLY trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BFLY's P/E ratio is -15.90. In terms of profitability, RMD's ROE is +0.24%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, RMD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BFLY's competition here
RMD vs ATEC Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $193.14, while ATEC trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ATEC's P/E ratio is -9.53. In terms of profitability, RMD's ROE is +0.24%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, RMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ATEC's competition here
RMD vs INSP Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $193.14, while INSP trades at $41.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas INSP's P/E ratio is 9.53. In terms of profitability, RMD's ROE is +0.24%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INSP's competition here
RMD vs IRMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $193.14, while IRMD trades at $94.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas IRMD's P/E ratio is 51.58. In terms of profitability, RMD's ROE is +0.24%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RMD is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IRMD's competition here
RMD vs AVNS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $193.14, while AVNS trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas AVNS's P/E ratio is -15.63. In terms of profitability, RMD's ROE is +0.24%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RMD is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AVNS's competition here
RMD vs SILK Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $193.14, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SILK's P/E ratio is -18.96. In terms of profitability, RMD's ROE is +0.24%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SILK's competition here
RMD vs FNA Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $193.14, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas FNA's P/E ratio is -19.83. In terms of profitability, RMD's ROE is +0.24%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check FNA's competition here
RMD vs CNMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CNMD has a market cap of 1B. Regarding current trading prices, RMD is priced at $193.14, while CNMD trades at $34.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CNMD's P/E ratio is 19.48. In terms of profitability, RMD's ROE is +0.24%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CNMD's competition here
RMD vs AORT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, AORT has a market cap of 989.3M. Regarding current trading prices, RMD is priced at $193.14, while AORT trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas AORT's P/E ratio is 81.52. In terms of profitability, RMD's ROE is +0.24%, compared to AORT's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AORT's competition here
RMD vs CSII Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RMD is priced at $193.14, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CSII's P/E ratio is -20.83. In terms of profitability, RMD's ROE is +0.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check CSII's competition here
RMD vs INMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, INMD has a market cap of 820.9M. Regarding current trading prices, RMD is priced at $193.14, while INMD trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas INMD's P/E ratio is 10.00. In terms of profitability, RMD's ROE is +0.24%, compared to INMD's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INMD's competition here
RMD vs LMRI Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, LMRI has a market cap of 781.1M. Regarding current trading prices, RMD is priced at $193.14, while LMRI trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas LMRI's P/E ratio is -20.85. In terms of profitability, RMD's ROE is +0.24%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, RMD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LMRI's competition here
RMD vs CRY Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RMD is priced at $193.14, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CRY's P/E ratio is 425.71. In terms of profitability, RMD's ROE is +0.24%, compared to CRY's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CRY's competition here
RMD vs SSII Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SSII has a market cap of 706.5M. Regarding current trading prices, RMD is priced at $193.14, while SSII trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SSII's P/E ratio is -70.60. In terms of profitability, RMD's ROE is +0.24%, compared to SSII's ROE of -0.23%. Regarding short-term risk, RMD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SSII's competition here
RMD vs CBLL Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CBLL has a market cap of 688.3M. Regarding current trading prices, RMD is priced at $193.14, while CBLL trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CBLL's P/E ratio is -11.20. In terms of profitability, RMD's ROE is +0.24%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, RMD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CBLL's competition here
RMD vs SIBN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SIBN has a market cap of 663.9M. Regarding current trading prices, RMD is priced at $193.14, while SIBN trades at $14.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SIBN's P/E ratio is -38.38. In terms of profitability, RMD's ROE is +0.24%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, RMD is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SIBN's competition here
RMD vs SRDX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RMD is priced at $193.14, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RMD's ROE is +0.24%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, RMD is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SRDX's competition here
RMD vs BVS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BVS has a market cap of 606.3M. Regarding current trading prices, RMD is priced at $193.14, while BVS trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BVS's P/E ratio is 21.83. In terms of profitability, RMD's ROE is +0.24%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BVS's competition here
RMD vs APEN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RMD is priced at $193.14, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas APEN's P/E ratio is -9.43. In terms of profitability, RMD's ROE is +0.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RMD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check APEN's competition here
RMD vs TCMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, TCMD has a market cap of 569.5M. Regarding current trading prices, RMD is priced at $193.14, while TCMD trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas TCMD's P/E ratio is 29.02. In terms of profitability, RMD's ROE is +0.24%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TCMD's competition here
RMD vs BWAY Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BWAY has a market cap of 565.2M. Regarding current trading prices, RMD is priced at $193.14, while BWAY trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BWAY's P/E ratio is 65.50. In terms of profitability, RMD's ROE is +0.24%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, RMD is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BWAY's competition here
RMD vs ZIMV Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RMD is priced at $193.14, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RMD's ROE is +0.24%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ZIMV's competition here
RMD vs NPCE Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, NPCE has a market cap of 532.9M. Regarding current trading prices, RMD is priced at $193.14, while NPCE trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas NPCE's P/E ratio is -24.05. In terms of profitability, RMD's ROE is +0.24%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NPCE's competition here
RMD vs CTKB Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CTKB has a market cap of 521.7M. Regarding current trading prices, RMD is priced at $193.14, while CTKB trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CTKB's P/E ratio is -6.97. In terms of profitability, RMD's ROE is +0.24%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CTKB's competition here
RMD vs CERS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CERS has a market cap of 521M. Regarding current trading prices, RMD is priced at $193.14, while CERS trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CERS's P/E ratio is -52.00. In terms of profitability, RMD's ROE is +0.24%, compared to CERS's ROE of -0.15%. Regarding short-term risk, RMD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CERS's competition here
RMD vs KIDS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, KIDS has a market cap of 468.2M. Regarding current trading prices, RMD is priced at $193.14, while KIDS trades at $18.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas KIDS's P/E ratio is -10.85. In terms of profitability, RMD's ROE is +0.24%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RMD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check KIDS's competition here
RMD vs VREX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, VREX has a market cap of 433.2M. Regarding current trading prices, RMD is priced at $193.14, while VREX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas VREX's P/E ratio is -5.14. In terms of profitability, RMD's ROE is +0.24%, compared to VREX's ROE of -0.18%. Regarding short-term risk, RMD is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check VREX's competition here
RMD vs PACB Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PACB has a market cap of 428.6M. Regarding current trading prices, RMD is priced at $193.14, while PACB trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PACB's P/E ratio is -3.37. In terms of profitability, RMD's ROE is +0.24%, compared to PACB's ROE of -4.88%. Regarding short-term risk, RMD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PACB's competition here
RMD vs PMI Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PMI has a market cap of 411.5M. Regarding current trading prices, RMD is priced at $193.14, while PMI trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PMI's P/E ratio is -0.35. In terms of profitability, RMD's ROE is +0.24%, compared to PMI's ROE of +4.99%. Regarding short-term risk, RMD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PMI's competition here
RMD vs CLPT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CLPT has a market cap of 401.3M. Regarding current trading prices, RMD is priced at $193.14, while CLPT trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CLPT's P/E ratio is -13.38. In terms of profitability, RMD's ROE is +0.24%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, RMD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CLPT's competition here
RMD vs OFIX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, OFIX has a market cap of 391.7M. Regarding current trading prices, RMD is priced at $193.14, while OFIX trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas OFIX's P/E ratio is -6.46. In terms of profitability, RMD's ROE is +0.24%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check OFIX's competition here
RMD vs VMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, VMD has a market cap of 380.3M. Regarding current trading prices, RMD is priced at $193.14, while VMD trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas VMD's P/E ratio is 26.81. In terms of profitability, RMD's ROE is +0.24%, compared to VMD's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check VMD's competition here
RMD vs DCTH Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, DCTH has a market cap of 377.7M. Regarding current trading prices, RMD is priced at $193.14, while DCTH trades at $10.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas DCTH's P/E ratio is 1094.00. In terms of profitability, RMD's ROE is +0.24%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RMD is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check DCTH's competition here
RMD vs AVR Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, AVR has a market cap of 343.6M. Regarding current trading prices, RMD is priced at $193.14, while AVR trades at $9.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas AVR's P/E ratio is -4.21. In terms of profitability, RMD's ROE is +0.24%, compared to AVR's ROE of -1.24%. Regarding short-term risk, RMD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AVR's competition here
RMD vs LAB Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, LAB has a market cap of 313.5M. Regarding current trading prices, RMD is priced at $193.14, while LAB trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas LAB's P/E ratio is -6.18. In terms of profitability, RMD's ROE is +0.24%, compared to LAB's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LAB's competition here
RMD vs SMLR Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RMD is priced at $193.14, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RMD's ROE is +0.24%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, RMD is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SMLR's competition here
RMD vs ELMD Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ELMD has a market cap of 307.1M. Regarding current trading prices, RMD is priced at $193.14, while ELMD trades at $37.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ELMD's P/E ratio is 31.70. In terms of profitability, RMD's ROE is +0.24%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, RMD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ELMD's competition here
RMD vs MASS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, MASS has a market cap of 306.3M. Regarding current trading prices, RMD is priced at $193.14, while MASS trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas MASS's P/E ratio is -8.35. In terms of profitability, RMD's ROE is +0.24%, compared to MASS's ROE of -0.26%. Regarding short-term risk, RMD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MASS's competition here
RMD vs SENS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SENS has a market cap of 297.8M. Regarding current trading prices, RMD is priced at $193.14, while SENS trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SENS's P/E ratio is -3.62. In terms of profitability, RMD's ROE is +0.24%, compared to SENS's ROE of -1.30%. Regarding short-term risk, RMD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SENS's competition here
RMD vs SGHT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SGHT has a market cap of 251.9M. Regarding current trading prices, RMD is priced at $193.14, while SGHT trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SGHT's P/E ratio is -6.61. In terms of profitability, RMD's ROE is +0.24%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, RMD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SGHT's competition here
RMD vs MGRM Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RMD is priced at $193.14, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas MGRM's P/E ratio is -11.11. In terms of profitability, RMD's ROE is +0.24%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, RMD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MGRM's competition here
RMD vs TMCI Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, TMCI has a market cap of 229M. Regarding current trading prices, RMD is priced at $193.14, while TMCI trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas TMCI's P/E ratio is -3.68. In terms of profitability, RMD's ROE is +0.24%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, RMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TMCI's competition here
RMD vs CATX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CATX has a market cap of 226M. Regarding current trading prices, RMD is priced at $193.14, while CATX trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CATX's P/E ratio is -2.07. In terms of profitability, RMD's ROE is +0.24%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CATX's competition here
RMD vs NVRO Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RMD is priced at $193.14, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RMD's ROE is +0.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RMD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check NVRO's competition here
RMD vs EYES Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RMD is priced at $193.14, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas EYES's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to EYES's ROE of -2.64%. Regarding short-term risk, RMD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EYES's competition here
RMD vs RXST Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, RXST has a market cap of 204.9M. Regarding current trading prices, RMD is priced at $193.14, while RXST trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas RXST's P/E ratio is -4.38. In terms of profitability, RMD's ROE is +0.24%, compared to RXST's ROE of -0.17%. Regarding short-term risk, RMD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check RXST's competition here
RMD vs APYX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, APYX has a market cap of 199.7M. Regarding current trading prices, RMD is priced at $193.14, while APYX trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas APYX's P/E ratio is -21.68. In terms of profitability, RMD's ROE is +0.24%, compared to APYX's ROE of -0.91%. Regarding short-term risk, RMD is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check APYX's competition here
RMD vs PROF Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, PROF has a market cap of 198.8M. Regarding current trading prices, RMD is priced at $193.14, while PROF trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas PROF's P/E ratio is -5.30. In terms of profitability, RMD's ROE is +0.24%, compared to PROF's ROE of -0.71%. Regarding short-term risk, RMD is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PROF's competition here
RMD vs ANIK Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, ANIK has a market cap of 194.3M. Regarding current trading prices, RMD is priced at $193.14, while ANIK trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas ANIK's P/E ratio is -18.48. In terms of profitability, RMD's ROE is +0.24%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, RMD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ANIK's competition here
RMD vs BSGM Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RMD is priced at $193.14, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RMD's ROE is +0.24%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, RMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSGM's competition here
RMD vs MDGS Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RMD is priced at $193.14, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RMD's ROE is +0.24%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RMD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MDGS's competition here
RMD vs EDAP Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, RMD is priced at $193.14, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas EDAP's P/E ratio is -5.80. In terms of profitability, RMD's ROE is +0.24%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, RMD is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EDAP's competition here
RMD vs FOCL Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, FOCL has a market cap of 172.4M. Regarding current trading prices, RMD is priced at $193.14, while FOCL trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas FOCL's P/E ratio is -5.61. In terms of profitability, RMD's ROE is +0.24%, compared to FOCL's ROE of -1.37%. Regarding short-term risk, RMD is less volatile compared to FOCL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check FOCL's competition here
RMD vs INGN Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, INGN has a market cap of 164.1M. Regarding current trading prices, RMD is priced at $193.14, while INGN trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas INGN's P/E ratio is -6.66. In terms of profitability, RMD's ROE is +0.24%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INGN's competition here
RMD vs QIPT Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RMD is priced at $193.14, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RMD's ROE is +0.24%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RMD is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check QIPT's competition here
RMD vs QTRX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, QTRX has a market cap of 147.4M. Regarding current trading prices, RMD is priced at $193.14, while QTRX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas QTRX's P/E ratio is -1.33. In terms of profitability, RMD's ROE is +0.24%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RMD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check QTRX's competition here
RMD vs CVRX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, CVRX has a market cap of 143.3M. Regarding current trading prices, RMD is priced at $193.14, while CVRX trades at $5.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas CVRX's P/E ratio is -2.69. In terms of profitability, RMD's ROE is +0.24%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CVRX's competition here
RMD vs NNOX Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, NNOX has a market cap of 126.7M. Regarding current trading prices, RMD is priced at $193.14, while NNOX trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas NNOX's P/E ratio is -1.57. In terms of profitability, RMD's ROE is +0.24%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, RMD is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NNOX's competition here
RMD vs SNWV Comparison June 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 28B. In comparison, SNWV has a market cap of 125.1M. Regarding current trading prices, RMD is priced at $193.14, while SNWV trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.63, whereas SNWV's P/E ratio is 15.16. In terms of profitability, RMD's ROE is +0.24%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, RMD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SNWV's competition here